Shared on 19 Sep 25
Fair value Increased 1.41%Digital Diabetes Care Will Expand International Market Opportunities
Analysts have modestly raised Insulet’s price target, citing strong Q2 earnings, accelerated international Omnipod 5 adoption, and favorable reimbursement trends outweighing regulatory risks, resulting in a consensus target increase from $355.17 to $360.17. Analyst Commentary Bullish analysts cited Insulet's beat on Q2 earnings estimates, which prompted broad guidance raises and higher outlooks for FY25, reflecting renewed momentum in core business metrics.
Shared on 04 Sep 25
Fair value Increased 0.50%Digital Diabetes Care Will Expand International Market Opportunities
Analysts remain bullish on Insulet due to accelerating revenue growth, increased guidance, and strong international momentum—particularly from Omnipod and favorable reimbursement trends—offsetting sector regulatory concerns, resulting in an unchanged consensus price target of $353.39. Analyst Commentary Bullish analysts cite Insulet's Q2 results showing reaccelerated growth, with revenue and earnings surpassing estimates and driving market share gains, especially among MDI conversions.
Shared on 07 May 25
Fair value Increased 8.09%Digital Diabetes Care Will Expand International Market Opportunities
Shared on 30 Apr 25
Fair value Decreased 0.04%FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 0.21%FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.36%FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 5.92%FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 7.80%FDA Clearance And Global Rollout Of Omnipod 5 Will Expand Market Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.